Abbott (ABT) director Kevin Conroy receives 231 stock equivalent units as fees

Rhea-AI Filing Summary

Abbott Laboratories director Kevin T. Conroy reported a compensation-related award of stock equivalent units. On this Form 4, he acquired 231 stock equivalent units at a reference price of $90.74 per unit, bringing his total reported holdings of this derivative instrument to 231 units.

The award represents director fees credited to a stock equivalent unit account under a grantor trust established by the director. These units track Abbott common share performance and are paid in cash, generally at age 65 or upon retirement from the board, rather than involving open-market share purchases or sales.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Conroy Kevin T

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Equivalent Units	231	$90.74	$21K

Holdings After Transaction: Stock Equivalent Units — 231 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock equivalent units granted: 231 units Reference price per unit: $90.74 per unit Total stock equivalent units after grant: 231 units +2 more

5 metrics

Stock equivalent units granted 231 units Grant of stock equivalent units on June 30, 2026

Reference price per unit $90.74 per unit Valuation of stock equivalent unit grant

Total stock equivalent units after grant 231 units Holdings following reported transaction

Underlying common shares 231 shares Underlying Abbott common shares linked to units

Conversion or exercise price $0.00 Reported conversion/exercise price for the units

Key Terms

Stock Equivalent Units, grantor trust, director fees, underlying security

4 terms

Stock Equivalent Units financial

"security_title: "Stock Equivalent Units" and footnote explaining the units"

Stock equivalent units are financial claims or instruments that are treated as if they were actual shares for purposes like calculating ownership, dilution, and earnings per share. Think of them as promises or placeholders for future slices of company pie—options, restricted units, or convertible securities—that don’t yet sit on the table but will reduce each existing slice when converted. Investors track them because they change how much of a company each share really represents and can affect valuation and voting power.

grantor trust financial

"under a grantor trust established by the director and paid, in cash"

A grantor trust is a legal arrangement where the person who puts assets into the trust keeps enough control or rights that, for tax and legal purposes, those assets are treated as still belonging to that person. For investors, that matters because income, gains and losses generated by the trust typically flow through to the grantor (or directly to investors) for tax reporting and distributions, affecting after-tax returns and cash flow predictability — think of it like a mailbox that forwards all the mail back to the sender rather than holding it inside.

director fees financial

"Director fees credited to a stock equivalent unit account under a grantor trust"

underlying security financial

"underlying_security_title: "Common Shares" and underlying_security_shares: "231.0000""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 05:28 PM Accepted by SEC EDGAR 07/01/2026 - 05:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Conroy Kevin T

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK ILLINOIS 60064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Equivalent Units	(1)	06/30/2026		A		231		(1)	(1)	Common Shares	231	$90.74	231	D

Explanation of Responses:

1. Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock.

	/s/ Kevin T. Conroy by Jessica H. Paik, Attorney-in-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Abbott Laboratories (ABT) report for Kevin T. Conroy?

Abbott Laboratories director Kevin T. Conroy reported an award of 231 stock equivalent units. These units represent deferred director fees tied to Abbott’s share performance rather than an open-market stock purchase or sale, and are settled in cash at a future date.

Is Kevin T. Conroy’s Form 4 transaction in ABT stock a buy or sell?

The Form 4 shows an acquisition coded as a grant or award, not an open-market buy or sell. Conroy received 231 stock equivalent units as director compensation, with no immediate trading of Abbott common shares reported in this filing.

How are Kevin T. Conroy’s stock equivalent units in Abbott (ABT) structured?

The 231 stock equivalent units are credited to a stock equivalent unit account under a grantor trust established by the director. They earn the same return as if invested in Abbott stock, but are paid out in cash, generally at age 65 or board retirement.

What is the reference price for Kevin T. Conroy’s stock equivalent unit grant at Abbott (ABT)?

The reported reference price for the grant is $90.74 per stock equivalent unit. This price is used to value the 231-unit director fee award, which tracks Abbott’s share performance but does not involve immediate issuance of common shares.

How many Abbott (ABT) stock equivalent units does Kevin T. Conroy hold after this transaction?

After the reported grant, Kevin T. Conroy’s total holding of this derivative instrument is 231 stock equivalent units. Each unit is linked to an equivalent number of underlying Abbott common shares for return purposes, but is ultimately settled in cash.